1397 related articles for article (PubMed ID: 28789511)
1. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
2. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
3. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
4. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
[TBL] [Abstract][Full Text] [Related]
5. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
6. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
Heidenreich A; Pfister D; Witthuhn R; Thüer D; Albers P
Eur Urol; 2009 Jan; 55(1):217-24. PubMed ID: 18926622
[TBL] [Abstract][Full Text] [Related]
7. Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.
Pietzak EJ; Assel M; Becerra MF; Tennenbaum D; Feldman DR; Bajorin DF; Motzer RJ; Bosl GJ; Carver BS; Sjoberg DD; Sheinfeld J
Urology; 2018 Aug; 118():114-118. PubMed ID: 29704586
[TBL] [Abstract][Full Text] [Related]
8. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
[TBL] [Abstract][Full Text] [Related]
9. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
[TBL] [Abstract][Full Text] [Related]
11. Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.
Syan-Bhanvadia S; Bazargani ST; Clifford TG; Cai J; Miranda G; Daneshmand S
Eur Urol; 2017 Nov; 72(5):814-820. PubMed ID: 28325537
[TBL] [Abstract][Full Text] [Related]
12. Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor.
Luz MA; Kotb AF; Aldousari S; Brimo F; Tanguay S; Kassouf W; Aprikian AG
World J Surg Oncol; 2010 Nov; 8():97. PubMed ID: 21062470
[TBL] [Abstract][Full Text] [Related]
13. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
14. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
15. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.
Considine S; Heaney R; Conroy R; Thornhill JA
Ir J Med Sci; 2016 Nov; 185(4):901-907. PubMed ID: 26692387
[TBL] [Abstract][Full Text] [Related]
16. Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study.
Dieckmann KP; Anheuser P; Kulejewski M; Gehrckens R; Feyerabend B
BMC Urol; 2018 Oct; 18(1):95. PubMed ID: 30367648
[TBL] [Abstract][Full Text] [Related]
17. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
18. Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor.
Venishetty N; Taylor J; Xi Y; Howard JM; Ng YS; Wong D; Woldu SL; De Leon AD; Pedrosa I; Margulis V; Bagrodia A
Clin Genitourin Cancer; 2024 Feb; 22(1):33-37. PubMed ID: 37468341
[TBL] [Abstract][Full Text] [Related]
19. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
20. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
